Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRAME family member 33 (PRAMEF33) is a protein-coding gene that is part of the PRAME gene family, which is generally classified as cancer/testis antigens—genes expressed predominantly in the testis and a variety of cancers. PRAMEF33 is predicted to function as a ubiquitin-like ligase-substrate adaptor within the Cul2-RING ubiquitin ligase complex, likely contributing to proteasome-mediated protein degradation processes in the cytoplasm. However, experimental validation of its functional roles is limited, and unlike the canonical PRAME gene, there is no clear evidence that PRAMEF33 is directly involved in tumorigenesis or is targeted by drugs or immunotherapies. Its expression profile, regulatory mechanisms, and pathogenic relevance remain poorly characterized. It has several aliases, some of which arose from previous gene annotation, but "PRAME family member 33" (PRAMEF33) is the standardized designation. As such, PRAMEF33 is not considered a therapeutic target; rather, it represents a member of a broader gene family with potential—but unverified—biological and disease significance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PRAME family member 33 (PRAMEF33).